Novo Nordisk invests DKK 500 million in a new raw material warehouse in Denmark

Novo Nordisk invests DKK 500 million in a new raw material warehouse in Denmark

Bagsværd, Denmark, 3 September 2015--Novo Nordisk just announced that the company is investing 500 million Danish kroner in a new 19,000 m2 warehouse in Hillerød, Denmark. The warehouse will handle all inbound raw materials for Novo Nordisk's production in Denmark and will have a capacity of around 17,000 pallets.

Novo Nordisk's site in Hillerød currently has about 1,900 employees and 70 employees will work in the warehouse.

"The investment in Hillerød underpins our long-term plans to invest in Denmark. Hillerød is a strategic site in Novo Nordisk and we're consolidating our inbound flow of materials at this site," said Susanne Hundsbæk-Pedersen, senior vice president of Devices & Supply Chain Management, Novo Nordisk.

Groundbreaking will take place today, 3 September, and the warehouse is expected to be fully operational end 2017. 

About Novo Nordisk in Hillerød

Established in 1992, the Hillerød site has a total area of about 1,650,000 m2 of which about 90,000 m2 is used for production and R&D facilities. The site encompasses a facility for Device R&D and three production facilities. One with moulding and pre-assembly of components, one with filling, assembly and packaging of diabetes finished products and one with production of haemophilia API. Novo Nordisk has made ongoing investments on the site of approx 350 million per year in average.

Further information

 

 

Media:    
Anne Margrethe Hauge +45 3079 3450 [email protected]
  Investors:    
Peter Hugreffe Ankersen +45 3075 9085 [email protected]
Daniel Bohsen +45 3079 6376 [email protected]
Melanie Raouzeos +45 3075 3479 [email protected]
Frank Daniel Mersebach (US) +1 609 235 8567 [email protected]

 

 

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.